Analyst Price Targets — DYN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 15, 2025 1:38 pm | Gavin Clark-Gartner | Evercore ISI | $36.00 | $19.51 | TheFly | Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISI |
| December 11, 2025 12:22 pm | — | Stifel Nicolaus | $39.00 | $19.69 | TheFly | Dyne Therapeutics price target raised to $39 from $36 at Stifel |
| December 10, 2025 11:49 am | — | Oppenheimer | $40.00 | $18.44 | TheFly | Dyne Therapeutics upgraded to Outperform from Perform at Oppenheimer |
| December 9, 2025 12:40 pm | William Pickering | Tudor Pickering | $23.00 | $19.09 | StreetInsider | Dyne Therapeutics (DYN) PT Raised to $23 at Bernstein SocGen Group |
| December 9, 2025 11:49 am | — | Bernstein | $23.00 | $22.20 | TheFly | Dyne Therapeutics price target raised to $23 from $21 at Bernstein |
| December 8, 2025 5:06 pm | Michael E Ulz | Morgan Stanley | $50.00 | $22.20 | StreetInsider | Dyne Therapeutics (DYN) PT Raised to $50 at Morgan Stanley |
| December 8, 2025 2:26 pm | Brian Skorney | Robert W. Baird | $30.00 | $23.03 | StreetInsider | Baird Reiterates Outperform Rating on Dyne Therapeutics (DYN) |
| December 8, 2025 2:19 pm | Andrew Fein | H.C. Wainwright | $60.00 | $23.52 | TheFly | Dyne Therapeutics price target raised to $60 from $46 at H.C. Wainwright |
| December 8, 2025 12:40 pm | Michael Freeman | Raymond James | $40.00 | $23.38 | StreetInsider | Dyne Therapeutics (DYN) PT Raised to $40 at Raymond James |
| November 25, 2025 11:15 am | — | Bernstein | $21.00 | $21.67 | TheFly | Dyne Therapeutics price target raised to $21 from $12 at Bernstein |
Latest News for DYN
- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 -
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:
- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD -
BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry.
Keros Therapeutics KROS is a clinical-stage biopharmaceutical company developing innovative therapies for patients with disorders caused by abnormal signaling within the transforming growth factor-beta (TGF-β) protein family.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DYN.
U.S. House Trading
No House trades found for DYN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.